Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01158157 · ClinicalTrials.gov registry record · Phase 3
VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV
A Phase 3 study of Smallpox Vaccine Adverse Reaction, sponsored by Emergent BioSolutions.
- Completed
- Registry status
- Phase 3
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT01158157 is a Phase 3 study of Smallpox Vaccine Adverse Reaction that has completed, run by Emergent BioSolutions. The registered enrollment target is 25 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01158157, a Phase 3 study of Smallpox Vaccine Adverse Reaction, has completed, sponsored by Emergent BioSolutions.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to vaccinate plasma donors with ACAM2000 smallpox vaccine for collection of plasma to be used in the manufacturing of Vaccinia Immune Globulin Intravenous (VIGIV).
Conditions Studied
Interventions
- BIOLOGICAL ACAM2000
Study Locations (1)
Florida
- Cangene Plasma Resources, Mid-Florida - Altamonte Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2010-09-13 |
| Est. Completion | 2012-02-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01158157
The ClinicalTrials.gov registry entry for NCT01158157 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emergent BioSolutions, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Smallpox Vaccine Adverse Reaction appearing as the primary indexed condition, and to 1 intervention - of which ACAM2000 is the first listed.
NCT01158157 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT01158157 about?
NCT01158157 is a clinical study titled "VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV". The purpose of this study is to vaccinate plasma donors with ACAM2000 smallpox vaccine for collection of plasma to be used in the manufacturing of Vaccinia Immune Globulin Intravenous (VIGIV).
What is the current status of trial NCT01158157?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 25 participants. The study started on 2010-09-13. Estimated completion is 2012-02-14.
What conditions does trial NCT01158157 study?
This clinical trial studies the following conditions: Smallpox Vaccine Adverse Reaction.
What interventions are being tested in trial NCT01158157?
The interventions under investigation include: ACAM2000 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01158157?
This trial is sponsored by Emergent BioSolutions, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01158157 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.